New drug shows promise for slowing kidney disease in alport syndrome

NCT ID NCT06425055

Completed Disease control Sponsor: Enyo Pharma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called vonafexor in 26 people with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug is safe and if it can help protect kidney function. Participants took increasing doses over 24 weeks. The study is now complete, and results will show whether vonafexor might be a future treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vonafexor (also called EYP001a), an oral drug taken as a tablet once daily
What this could lead to: If it works, this could point toward a treatment to slow kidney decline in Alport syndrome, potentially delaying the need for dialysis or transplant.
What could go wrong: This is a small, early proof-of-concept study with only 26 participants, so results may not apply to everyone. The drug may not improve kidney function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alport syndrome hereditary nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPORT SYNDROME

Contacts and locations

Locations

Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine

Los Angeles, California, 90095, United States
Dr Ankit Mehta - Renal Disease Research Institute

Dallas, Texas, 75126, United States
Dr Arnold Silva - Boise Kidney & Hypertension

Boise, Idaho, 83703, United States
Dr Eric Wallace - University of Alabama

Birmingham, Alabama, 35294, United States
Dr James Simon - Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dr Moglie Le Quintrec - Hopital Lapeyronie

Montpellier, 34090, France
Dr Suneel Udani - NANI Research

Hinsdale, Illinois, 60521, United States
Dr Tingting Li - Washington University

St Louis, Missouri, 63110, United States
Fundacio Puigvert

Barcelona, 08025, Spain
Fundacion Jimenez Diaz

Madrid, 28040, Spain
Hospital Virgen de la Arrixaca

El Palmar, 30120, Spain
Pr Claire Rigothier - CHU De Bordeaux

Bordeaux, 33076, France
Pr. Bertrand Knebelmann - Necker Enfants Malades

Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.